Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CHIEF FINANCIAL OFFICER

SVP, CHINA OPERATIONS

Chief Financial Officer

SVP, China Operations

Interim CEO

EVP, Chief Medical Officer

Chief Commercial Officer

Chief Executive Officer

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-01	Premium	sold (taxes)	Premium	Premium	Premium	CEO
2024-03-22	Premium	sold (taxes)	Premium	Premium	Premium	CEO
2024-03-07	Premium	bought	Premium	Premium	Premium	CEO
2024-03-07	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-03-06	Premium	acquired	Premium	Premium	Premium	SVP, CHINA OPERATIONS
2024-03-06	Premium	sold (taxes)	Premium	Premium	Premium	CEO
2024-03-06	Premium	acquired	Premium	Premium	Premium	CEO
2024-03-06	Premium	sold (taxes)	Premium	Premium	Premium	SVP, CHINA OPERATIONS
2024-03-06	Premium	acquired	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-03-06	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-02-21	Premium	acquired	Premium	Premium	Premium	CEO
2024-02-21	Premium	acquired	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-02-21	Premium	acquired	Premium	Premium	Premium	SVP, CHINA OPERATIONS
2024-02-01	Premium	sold (taxes)	Premium	Premium	Premium	CEO
2023-12-22	Premium	sold (taxes)	Premium	Premium	Premium	CEO
2023-12-07	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-12-06	Premium	sold (taxes)	Premium	Premium	Premium	SVP, China Operations
2023-12-06	Premium	sold (taxes)	Premium	Premium	Premium	CEO
2023-12-06	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-11-01	Premium	sold (taxes)	Premium	Premium	Premium	CEO
2023-09-22	Premium	sold (taxes)	Premium	Premium	Premium	Interim CEO
2023-09-07	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-09-06	Premium	sold (taxes)	Premium	Premium	Premium	SVP, China Operations
2023-09-06	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Chief Medical Officer
2023-09-06	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer

FGEN - FibroGen Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for FGEN